[{"id":"76368fa4-a1db-4965-8029-9b8984def53d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01780545","created_at":"2021-01-18T07:50:59.069Z","updated_at":"2024-07-02T16:36:07.518Z","phase":"Phase 2","brief_title":"Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer","source_id_and_acronym":"NCT01780545","lead_sponsor":"Noah Hahn, M.D.","biomarkers":" HSPB1","pipe":" | ","alterations":" HSPB1 expression","tags":["HSPB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HSPB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • apatorsen (OGX-427)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2022-07-11"}]